However, excessive muscle loss can be detrimental to metabolism , strength , and overall health

launch pending approval Zepbound Kwikpen regulatory action Lilly Q1 2026 earnings (early May) Novo Q1 2026 earnings (early May, watch for any GLP-1 psychiatric trial announcements) Q3 and Q4 2026 Retatrutide TRIUMPH-1, TRIUMPH-2, TRIUMPH-3 topline readouts (obesity, OSA) Retatrutide TRANSCEND-T2D readouts (diabetes) Orforglipron ACHIEVE-4 Phase 3 T2D readout Brenipatide for MDD Phase 3 trial initiation Eloralintide Phase 3 initiation 2027 Expected earliest topline results for brenipatide Phase 3 in alcohol use disorder Expected earliest topline results for brenipatide Phase 3 in bipolar disorder Possible regulatory submissions for retatrutide in lead obesity indications Lilly R&D Day announcements expanding the brenipatide program to additional indications (likely) 2028 Earliest realistic FDA decision on brenipatide for AUD assuming successful Phase 3 Phase 2 readouts for brenipatide in smoking, opioid use disorder, and asthma None of these dates are guaranteed

The Two Components: Different Mechanisms, Complementary Roles To understand why the ratio matters, the two components need to be understood separately first
It covers a physician review of your health history and, if the physician determines treatment is appropriate, a prescription with refills for up to one year, sent to the pharmacy you choose
Plateau while taking GLP-1 medication: What to do next